Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for MiNK Therapeutics in a ...

MiNK Therapeutics (NASDAQ:INKT – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a ...

Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic partnerships while navigating financial hurdles and leadership changes.

Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded. (Operator Instructions) I'd now like to hand the call over ...

We ended the year with a cash balance of $4.6 million. Cash used in operations for the three and twelve months ended December 31, 2024, was $1.7 million, and $9.6 million, respectively, compared to $3 ...

MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe ...

Mashable is a global, multi-platform media and entertainment company.

GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators ...

Type 1 invariant (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to ...